A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation—KRAS circulating tumor DNA—strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma.
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.
Immunovia announced results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test.
Researchers and pediatric neurosurgeons at the University of Pittsburgh School of Medicine and UPMC Children’s Hospital of Pittsburgh developed a new way to profile brain cancers in children.
Cervical cancer diagnoses among rural U.S. women have been increasing since 2012, after years of decreases, according to research from MUSC Hollings Cancer Center and the University of Texas MD Anderson Cancer Center.
The American College of Radiology Lung Cancer Screening Registry is expanding and will evolve into the Early Lung Cancer Detection Registry in late 2025.
Driven by a steady influx of retirees, Florida now has the highest leukemia rates of any U.S. state and the disease is the fastest-rising cancer type statewide, according to research from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.
In a phase I study, rhenium obisbemeda (186RNL)—an investigational drug developed at the University of Texas Health Science Center at San Antonio—more than doubled median survival and progression-free time, compared with standard median survival and progression rates.
The Wistar Institute’s Paul M. Lieberman and his lab identified and tested a method for targeting certain cancers caused by Epstein-Barr Virus.
